CST-107 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-006067-28-BE (EUCTR)		18/11/2021	A study to investigate if CST-103 and CST-107 has an effect on the brain in patients with progressive disease of the nervous system.	A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neurodegenerative Disorders - PD Effects of CST-103/CST-107 on CNS in Neurodegenerative Disorders	Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia. MedDRA version: 24.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10009846;Term: Cognitive impairment;Classification code 10067889;Term: Dementia with Lewy bodies;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Spiropent Product Name: Spiropent Product Code: CST-103 INN or Proposed INN: Clenbuterol Hydrochloride Product Name: Nadolol Product Code: CST-107 INN or Proposed INN: Nadolol	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Belgium;Australia;United Kingdom;New Zealand